First injectable for cellulite approved
This article provided by ONU HealthWise Pharmacy.
The US Food and Drug Administration (FDA) has approved the first injectable medication for cellulite.
This medication is called Qwo (collagenase clostridium histolyticum-aaes). The FDA approved it to treat adult women with moderate to severe cellulite in the buttocks.
Qwo comes in the form of an injection and is given under the skin (subcutaneously) of each buttock by your health care provider.
You may receive up to 12 injections per treatment area. Each treatment visit may include up to two treatment areas.
These injections will be given 21 days apart for three treatment visits.
Common side effects of Qwo may include hardness, bruising, discoloration, itching, pain, redness, swelling and warmth in the area being treated.
Tell your health care provider before receiving this injection if you have a bleeding problem or if you take blood thinners or similar medications. This medication must be used with caution in those with bleeding abnormalities or those who take antiplatelet or anticoagulant medication.
People can expect this injection to be available in Spring 2021. Approval was granted to Endo International plc.
Stories Posted This Week
Friday, August 1, 2025
Thursday, July 31, 2025
- Bluffton University names Dr. J. Alexander Sider as next President
- GLP-1s and weight loss: Impact on muscles
- Check out August 2025 at Bluffton Public Library
- Discovery Days prize drawing results, check your tickets
- Wesley “Wes” Allen Leightner worked for Phillips
- How floundering Cards should deal at deadline
Wednesday, July 30, 2025
- Letter: BOHS work night at the Depot, July 30
- County park district considers name change, invites feedback
- Teen vaccine clinic at Bluffton Middle School, August 18
- State of Ohio expands commercial truck parking at US 30 rest areas
- National Night Out celebration is August 5
- Bluffton council hears neighbor concerns about proposed school practice field
- GROB Systems to host 5-AXIS LIVE! with 21 industry partners on Aug. 5